Frequent immune responses to a cancer/testis antigen, CAGE, in patients with microsatellite instability - Positive endometrial cancer
Frequent immune responses to a cancer/testis antigen, CAGE, in patients with microsatellite instability - Positive endometrial cancer
复制标题
DOI：
10.1158/1078-0432.ccr-04-1702
复制
发表时间：
2005-05-15
影响因子：
11.5
通讯作者：
Kawakami, Y
中科院分区：
文献类型：
--
作者：
Iwata, T;Fujita, T;Kawakami, Y
Please try later.
Purpose: Identification of cancer/testis antigens useful for diagnosis or immunotherapy of cancers was attempted by c DNA expression cloning with patients'sera (SEREX).Experimental Design: cDNA expression libraries made from testis or endometrial cancer cell lines were screened using sera from patients with endometrial cancer or melanoma patients immunized with dendritic cells pulsed with autologous tumor lysates. Tissue-specific expression by RTPCR and immunogenicity by Western blotting of the bacterial recombinant antigen with sera from cancer patients were evaluated.Results: A cancer/testis antigen, CAGE, was isolated by two independently performed SEREX. CAGE was expressed in various cancer cell lines including enclometrial cancer, colon cancer, and melanoma in 7 of 10 enclometrial cancer tissues and in 1 of 3 atypical endometrial hyperplasia, but not in normal tissues including the endometrium and testis. The protein expression on cancer cells was confirmed by Western blot analysis with the recombinant CAGE protein, anti-CAGE IgG antibody was detected in sera from 5 of 45 enclometrial cancer, 2 of 24 melanoma, and 2 of 33 colon cancer patients, but not in sera from healthy individuals. By ELISA analysis, anti-CAGE antibody was detected in 12 of 45 enclometrial cancer, 2 of 20 melanoma, and 4 of 33 colon cancer patients. Intriguingly, anti-CAGE antibody was highly positive in 7 of the 13 (53.8%) microsatellite instability (MSI)-H patients with enclometrial cancer, but negative in 20 non - MSI-H patients (P = 0.001).Conclusion: CAGE may be useful for immunotherapy and diagnosis of various cancers particularly MSI-positive enclometrial cancer.